secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001140361-25-009063
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Pharma appoints Thomas Trimarchi as President and CFO; former CFO departs
--------------------------------------------------------------------------------

- Brian Stephenson's employment ended March 17, 2025; receives 9 months base salary and COBRA.
- Stephenson to serve as consultant from March 17, 2025 through March 17, 2026.
- Thomas Trimarchi appointed President and CFO; effective immediately.
- Stephenson's departure is for personal reasons and not due to any disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125009063/0001140361-25-009063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125009063/ef20045625_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-009063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer